1.1Methylthio group at R1
A methylthio group uses a core–S–CH3 linkage. The larger sulfur atom gives the core-to-methyl linkage a longer bond path than an ether linkage.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A methylthio group uses a core–S–CH3 linkage. The larger sulfur atom gives the core-to-methyl linkage a longer bond path than an ether linkage.
The nitrogen forms three bonds, one to the core, one to methyl carbon, and one to cyclopropyl carbon. The cyclopropyl ring constrains its own carbon framework while rotation about the nitrogen-to-cyclopropyl bond remains available.
The nitrile withdraws electron density through the attached scaffold and presents a terminal nitrogen as a hydrogen-bond acceptor. The carbon–nitrogen triple bond keeps the substituent linear.
The oxygen forms a C–O–C bridge that joins the two fragments through a bent linkage. The ether oxygen supplies a hydrogen-bond acceptor at the junction.
The C=S group retains a trigonal planar bridge carbon and the two attachment bonds to the surrounding fragments. The larger sulfur atom extends farther from the bridge carbon than oxygen in a carbonyl.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
The cereblon-recruiting dual degrader serves as a research reagent in canine lymphoma cell cultures. Matched wells receive the degrader, its unconjugated target-binding ligand, or vehicle. Immunoblotting with antibodies validated for canine BCL-XL and BCL-2 measures the abundance of both proteins, and a parallel viability assay measures the cellular response.
A trans-1,4-cyclohexanediyl unit replaces a flexible hexamethylene segment at L2. The two adjoining linker segments attach at opposite ring carbons in the trans configuration, connecting the target-binding and cereblon-binding ends through a conformationally restricted spacer. A matched pair of compounds with the same terminal ligands and different L2 segments is tested for depletion of BCL-XL and BCL-2.
Three compounds use straight saturated L1 segments with 3, 5, or 7 backbone carbons and share the same L2, L3, and terminal ligands. Replicate cell cultures receive each compound at 10, 100, and 1000 nanomolar. Samples collected at 2, 6, and 24 hours provide separate BCL-XL and BCL-2 measurements normalized to time-matched vehicle controls.
A microfluidic culture chip holds tumor spheroids in chambers connected to a medium inlet and an effluent outlet. A syringe pump passes degrader-containing medium through the chambers during exposure and switches to compound-free medium for washout. Individual spheroids are collected at defined intervals and lysed for separate measurements of BCL-XL and BCL-2 during exposure and recovery.
Two matched reporter cell lines carry a small luminescence-complementing peptide tag on endogenous BCL-XL or BCL-2, respectively. The degrader is added to both lines in parallel, and the tag signal is measured after addition of the complementary enzyme fragment and substrate. A time series normalized to vehicle wells tracks the abundance of each tagged protein, and immunoblotting in the unmodified parental line checks that the tags preserve the depletion response.
A liquid handler dispenses the dual degrader across a concentration series in multiwell plates and distributes vehicle controls across each plate. Software processes immunoassay signals for BCL-XL and BCL-2 from matched wells, normalizes them to the vehicle controls, and fits a separate concentration-response curve for each protein. The software generates a second plate layout with additional concentrations around each estimated half-maximal depletion point and extends the concentration range when the initial measurements fail to bracket that point.
At n1 = 2, one R4 site carries fluorine and the other carries methoxy. Fluorine bonds directly to the scaffold, and methoxy attaches through oxygen in a scaffold–O–CH3 linkage.
Set n1 to 1 and place chlorine at the single R4 site. The chlorine forms one direct bond to the scaffold.
An unsubstituted methyl group occupies the R7 position. Its carbon forms one single bond to the attachment atom and carries three hydrogens.
L2 consists of four consecutive methylene groups, with one attachment at each end. The three internal carbon–carbon single bonds allow the segment to sample extended and bent conformations.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
D is aryl or heteroaryl; is 0, 1, or 2; each R3 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(A · US 2011/0124627 A1 · ¶
in which RA is hydrogen, halogen, pentafluorosulfanyl, cyano, nitro, (C1-C4)-alkyl, hydroxyl, (C1-C4)-alkoxy, amino or a group of the formula —NH—C(═O)—R6, —NH—C(═O)—NH—R6 or —S(═O)n—R7, where (C1-C4)-alkyl and (C1-C4)-alkoxy may be up to trisubstituted by fluorine, and in which R6 is hydrogen or (C1-C4)-alkoxy which may be up to trisubstituted by fluorine, R7 is (C1-C4)-alkyl which may be substituted by hydroxyl, methoxy or ethoxy or up to trisubstituted by fluorine, and n iB · US 10,189,788 B2 · ¶ 19
R2 is —NR6R7; and each of R6 and R7 independently is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocylylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, or substituted heteroarylalkyl; or togetA · US 2011/0124627 A1 · ¶
A particular embodiment of the present invention comprises compounds of the formula (I) in which RA is hydrogen, fluorine, chlorine, bromine, cyano, nitro, methyl, trifluoromethyl, hydroxyl, methoxy, trifluoromethoxy or a group of the formula —S(═O)n—R7 in which R7 is methyl or trifluoromethyl, and n is the number 0 or 2, D is C—RD or N, in which RD is hydrogen or fluorine, E is C—H and G is C—RG or N, in which RG is hydrogen, fluorine or chlorine, and the salts, solvates andB · US 10,189,788 B2 · ¶ 65
D is aryl or heteroaryl; is 0, 1, or 2; each R3 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(A · US 2011/0124627 A1 · ¶
A particular embodiment of the present invention comprises compounds of the formula (I) in which RA is hydrogen, fluorine, chlorine, bromine, cyano, nitro, methyl, trifluoromethyl, hydroxyl, methoxy, trifluoromethoxy or a group of the formula —S(═O)n—R7 in which R7 is methyl or trifluoromethyl, and n is the number 0 or 2, D is C—RD or N, in which RD is hydrogen or fluorine, E is C—H and G is C—RG or N, in which RG is hydrogen, fluorine or chlorine, and the salts, solvates andB · US 10,189,788 B2 · ¶ 65
Z is H, halogen, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, cyano, azido, —C(O)H, —C(O)R8, —S(O)R8, —S(O)2R8, —S(O)2NR8R9, —C(O)OR8, or —C(O)NR9R10;A · US 2011/0124627 A1 · ¶
A particular embodiment of the present invention comprises compounds of the formula (I) in which RA is hydrogen, fluorine, chlorine, bromine, cyano, nitro, methyl, trifluoromethyl, hydroxyl, methoxy, trifluoromethoxy or a group of the formula —S(═O)n—R7 in which R7 is methyl or trifluoromethyl, and n is the number 0 or 2, D is C—RD or N, in which RD is hydrogen or fluorine, E is C—H and G is C—RG or N, in which RG is hydrogen, fluorine or chlorine, and the salts, solvates andB · US 10,189,788 B2 · ¶ 65
R2 is —NR6R7; and each of R6 and R7 independently is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocylylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, or substituted heteroarylalkyl; or togetA · US 2011/0124627 A1 · ¶
each L2 is independently alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocycylene, substituted carbocyclylene, heterocyclylene, substituted heterocyclylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, arylene-alkylene, heteroarylene-alkylene, arylene-heteroalkylene, substituted arylene-heteroalkylene, heteroarylene-heteroalkylene, substituted heA · US 2011/0124627 A1 · ¶ 14
each L2 is independently alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocycylene, substituted carbocyclylene, heterocyclylene, substituted heterocyclylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, arylene-alkylene, heteroarylene-alkylene, arylene-heteroalkylene, substituted arylene-heteroalkylene, heteroarylene-heteroalkylene, substituted heA · US 2011/0124627 A1 · ¶ 14
An empty cell means only that no passage was reproduced there.
This application relates generally to 3-deazapteridinone derivatives and pharmaceutical compositions which selectively modulate toll-like receptors (such as TLR-7), and methods of making and using such compounds.A · US 2011/0124627 A1 · ¶ 2
The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.B · US 10,189,788 B2 · ¶ 2
These findings show that the FP receptor is a therapeutic target protein for treatment of IPF [Olman, Nat.B · US 10,189,788 B2 · ¶ 6
patent.fyi, US 2026/0355323 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355323/, SHA-256 bb3b0021a1f92b699526e4b14f85a87103c056e4a3074eebf81d0249e0b76964